Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,750.00
Bid: 1,750.00
Ask: 1,750.50
Change: -6.00 (-0.34%)
Spread: 0.50 (0.029%)
Open: 1,743.50
High: 1,759.00
Low: 1,740.50
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK quarterly sales slip but confirms 2023 guidance

Wed, 26th Apr 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Wednesday as worries about the US banking sector returned.

Concern around the banking sector came to the fore again on Tuesday as shares in First Republic Bank collapsed by 49% in New York after it revealed customers pulled out more than USD100 billion of deposits last month.

The California-based lender said withdrawals had stabilised this month, but added that deposits continued to fall slightly.

The news brought back nervousness about the sector, having calmed recently following the chaos caused by the collapse of Silicon Valley Bank.

Other major US banks such as JPMorgan and Wells Fargo closed lower in response.

In London, pharmaceutical firm GSK reported lower turnover in the first quarter, due to lower Covid-19 related sales. Mexican miner Fresnillo said it made a solid start to 2023 as silver and gold production increased.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 17.23 points, or 0.2%, at 7,873.90

----------

Hang Seng: up 0.9% at 19,791.52

Nikkei 225: closed down 0.7% at 28,416.47

S&P/ASX 200: closed down 0.1% at 7,316.30

----------

DJIA: closed down 344.57 points, 1.0%, at 33,530.83

S&P 500: closed down 1.6% at 4,071.63

Nasdaq Composite: closed down 2.0% at 11,799.16

----------

EUR: higher at USD1.0995 (USD1.0983)

GBP: higher at USD1.2428 (USD1.2404)

USD: lower at JPY133.74 (JPY133.98)

Gold: higher at USD1,997.77 per ounce (USD1,987.63)

(Brent): higher at USD81.20 a barrel (USD80.52)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

11:00 BST UK CBI distributive trades survey

----------

German consumer morale rose sharply heading into May, a key survey showed, as concerns eased about the impact of high inflation on Europe's top economy. Pollster GfK said its forward-looking survey of around 2,000 people climbed 3.6 points to reach minus 25.7 points, the seventh consecutive monthly increase. Improving sentiment was driven by lower energy prices, government relief measures aimed at tackling high costs, and recent wage deals struck between various industries and workers, GfK said. "More and more households are assuming that feared losses in purchasing power due to inflation will turn out to be much milder," the pollster said.

----------

BROKER RATING CHANGES

----------

JPMorgan raises Associated British Foods price target to 1,850 (1,760) pence - 'neutral'

----------

Bernstein raises Whitbread price target to 3,150 (2,985) pence - 'market-perform'

----------

JPMorgan raises Travis Perkins price target to 850 (820) pence - 'underweight'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said its sales performance in the first quarter of 2023 reflected lower Covid-19 solution sales compared to the previous year. When excluding this Covid-related business, sales grew 10% at constant exchange rates. In the quarter, turnover totalled GBP6.95 billion, down from GBP7.19 billion the previous year. Pretax profit was GBP1.91 billion, down from GBP2.29 billion the year prior. Adjusted operating profit rose by 8% on a year before to GBP2.09 billion, and adjusted operating profit margin was 30.1%, up 3.1 percentage points. Despite, the fall in turnover and pretax profit, GSK affirmed its full-year guidance, expecting turnover growth of between 6% and 8%. It declared a quarterly dividend of 14 pence per share. It said it expects to payout 56.5p per share in dividends in 2023.

----------

Fresnillo reported a "solid" start to 2023, noting silver and gold production were both up on the previous quarter thanks to an increasing contribution from its new Juanicipio mine. Quarterly attributable silver production totalled 13.1 million ounces, up 5.1% against the previous quarter but down 0.9% against the previous year as a result of lower ore grade and decreased volume of ore processed at San Julian. Quarterly attributable gold production totalled 173,000 ounces, up 3.0% against the previous quarter and up 16% against the previous year due to the higher volume of ore processed. Looking forward, the miner kept its full-year guidance unchanged. It sees attributable silver production in the range of 57.0 million to 64.0 million ounces and attributable gold production in the range of 590,000 to 640,000 ounces.

----------

COMPANIES - FTSE 250

----------

Drax said it delivered a "strong" system support and generation performance in the first three months of 2023, as it announced a GBP150 million share buyback programme. The renewable energy company said it expects 2023 adjusted earnings before interest, tax, depreciation and amortisation to be in-line with analyst consensus estimates, which it placed at GBP1.16 billion in a range of GBP1.1 billion to GBP1.2 billion. Drax noted that at the end of March it formally closed its two remaining coal units at the Drax Power Station.

----------

Harbour Energy announced that the Kan-1 exploration well has made an oil discovery in Block 30, offshore Mexico. The oil company holds a 30% interest in the block. The Block 30 partners will now evaluate the well data collected and put together a proposed plan to appraise the discovery, Harbour said.

----------

Specialty chemicals company Elementis said overall trading in the first quarter of 2023 has been "resilient" against subdued market demand conditions. It reported that revenue was flat on an underlying basis in the quarter as benefits from prior year pricing actions and improved mix broadly offset weaker volumes. In its Performance Specialties division, Elementis said its underlying performance was below the prior year period due to continued challenging demand conditions across coatings markets. In its Personal Care division, its underlying performance improved on the prior year as volumes were broadly stable due to new product launches and new business success, which helped to offset market weakness in Asia. Chief Executive Paul Waterman said: "We have made a solid start to the year and will continue to maintain our focus on self-help actions and effectively managing the challenging demand environment. We remain on-track to deliver over USD50 million of new business opportunities, 15 new products and progress towards USD10 million of additional efficiency savings by year end."

----------

OTHER COMPANIES

----------

Unikmind Holdings said it bought 12.0 million more shares in Kape Technologies, representing a further 2.8% of its shares. The acquisition means that Unikmind now holds or has acceptances for its takeover offer totalling 79% of Kape shares. Unikmind's offer is USD3.60 per Kape share.

----------

Breedon said that trading during the first quarter of 2023 has been "positive", with "encouraging" levels of enquiries. Revenue in the quarter is expected to be 10% ahead of the same period last year, or 7% ahead on a like-for-like basis. As a result, the construction materials firm said it is trading in-line with expectations, which it did not specify. Chief Executive Rob Wood said: "Our teams have stayed close to their customers and we continue to manage our cost base prudently, enabling us to grow revenue while fully recovering input cost increases. Longer term, our end-market exposure remains underpinned by structural growth dynamics."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.